

BENJAMIN D EHST, MD, PHD

9495 SW Locust Street, Suite G
Portland, Oregon 97223
p - (503) 245-1525, f - (503) 245-0315
email - behst@oregonmedicalresearch.com

PROFESSIONAL EXPERIENCE

MEDICAL STAFF	Dermatologist <i>Baker Allergy, Asthma and Dermatology, Portland, OR</i>	Oct 2016 - PRESENT
	Investigator <i>Oregon Medical Research Center, Portland, OR</i>	Oct 2016 - PRESENT
	Dermatologist <i>HealthPartners, St. Paul, MN</i> <i>Regions Hospital, St. Paul, MN</i>	Oct 2015 - APR 2017
	Dermatologist <i>Oregon Health & Science University, Portland, OR</i> <i>Veteran's Administration Medical Center, Portland, OR</i>	Aug 2007 - SEP 2015
	Dermatologist, Consultants in Dermatology, LLC <i>Mid-Columbia Medical Center, The Dalles, OR</i> <i>Providence Seaside Medical Center, Seaside, OR</i>	2007 - 2012 2007 - 2008
ACADEMIC	Clinical Associate Professor	JUL 2017 - PRESENT
	Associate Professor	JUL 2015 - SEP 2015
	Assistant Professor <i>Department of Dermatology,</i> <i>Oregon Health & Science University, Portland, OR</i>	AUG 2007 - JUNE 2015
	Post-doctoral Research Fellow <i>Department of Molecular Microbiology and Immunology,</i> <i>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD</i> <i>Fidel Zavala, MD, Advisor</i>	JAN 2007 - JUL 2007
	Post-doctoral Research Fellow Graduate Research Assistant <i>Department of Microbiology and Center for Immunology,</i> <i>University of Minnesota, Minneapolis, MN</i> <i>Marc K. Jenkins, PhD, Advisor</i>	SPRING 2003 1998 - 2001
Research Assistant <i>Ben May Institute for Cancer Research and</i>	1995 - 1996	

Committee on Immunology, University of Chicago, Chicago, IL
Jeffrey A. Bluestone, PhD, Advisor

ADMINISTRATIVE	Director , Medical Dermatology <i>Department of Dermatology, Oregon Health & Science University, Portland, OR</i>	2010 - 2014
	Director , Consultants in Dermatology, LLC <i>Providence Seaside Medical Center, Seaside, OR and Mid-Columbia Medical Center, The Dalles, OR</i>	2010 - 2013
	Director , Dermatology Undergraduate Medical Education <i>Department of Dermatology, Oregon Health & Science University, Portland, OR</i>	2007 - 2010
	Supervising Physician for Physician Assistant Kim Sanders, PA-C, OR License #PA01062 <i>Department of Dermatology, Oregon Health & Science University, Portland, OR</i>	2008 - 2015
CONSULTANCY	<i>Novartis Pharmaceuticals Corp. – Dermatology, East Hanover, NJ</i> Advisory board and national speaker board member for psoriatic disease platform including anti-IL17 biologic secukinumab for plaque psoriasis	2017 – PRESENT
	<i>Regeneron Pharmaceuticals, Inc. – Dermatology, Tarrytown, NY</i> <i>Sanofi-Aventis US, LLC – Dermatology, Bridgewater, NJ</i> National speaker board member for anti-IL4/13 biologic dupilumab for atopic dermatitis	2017 – PRESENT
	<i>Lilly USA, LLC – Dermatology, Eli Lilly and Co., Indianapolis, IN</i> Advisory board (2014–present) and national speaker board (2017–present) member for clinical development of anti-IL17 biologic ixekizumab for plaque psoriasis	2014 – PRESENT
	<i>AbbVie Inc. – Dermatology, North Chicago, IL</i> Advisory board member for psoriatic disease platform including adalimumab biologic therapy for psoriasis	2015 – 2016
	<i>Janssen Biotech, Inc. – Dermatology, Horsham, PA</i> Advisory board member for psoriatic disease platform including ustekinumab biologic for psoriasis	2014 – 2016
	<i>Oregon Aesthetic Technologies, Portland, OR</i> Provided expert advice on design and implementation of a clinical trial of a device for treatment of acne titled “An evaluation of the safety and effectiveness of the BEAM device in the treatment of mild-to-moderate acne”	2010

Meagan Medical, Inc, Vancouver, WA 2009 - 2010
Provided expert advice on risks associated with use of a cutaneous field-stimulator device for chronic pain during FDA Pre-IDE application submission

SPECIALTY CERTIFICATION

Diplomate, American Board of Dermatology, No. 2007-016361 2007
Re-certified, 2017

LICENSE

Oregon, active status (expires 12/31/2019), No. MD27612 *Granted, 2007*

EDUCATION

POST-GRADUATE **JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE,** 2004 - 2007
BALTIMORE, MD
Resident, Department of Dermatology

UNIVERSITY OF SÃO PAULO, SÃO PAULO, BRAZIL JAN 2006
Visiting Resident, Department of Dermatology

HENNEPIN COUNTY MEDICAL CENTER, MINNEAPOLIS, MN 2003 - 2004
Chief Resident, Transitional Internship

GRADUATE **UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN** 1996 - 2003
Combined MD/PhD Program
MD (2003)
PhD (2002), *Microbiology, Immunology and Cancer Biology*

UNDERGRADUATE **UNIVERSITY OF CHICAGO, CHICAGO, IL** 1992 - 1996
AB with Honors, *Biological Sciences*

SCHOLARSHIP

RESEARCH INTERESTS

Dermatologic manifestations of HIV and other infectious diseases; Immunobiology of psoriasis and atopic dermatitis; Infectious complications of immunomodulating biologic drug use

GRANTS

Co-Principal Investigator, National Institute of Arthritis and Musculoskeletal and Skin Diseases, R03 2014 - 2015

“PIASy as a negative regulator of Th17 pathway in psoriasis”; Co-PI: Yuangang Liu, PhD

Sub-I, National Institute of Allergy and Infectious Diseases 2012 - 2015
Investigator-Initiated Study, “A Randomized Open Label Mechanistic Study with Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines”; PI: Jon Hanifin, MD

Sub-I, National Institute of Allergy and Infectious Diseases 2007 - 2015
Investigator-Initiated Study, “A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects”; PI: Jon Hanifin, MD

Sub-I, National Institute of Arthritis and Musculoskeletal and Skin Diseases 2006 - 2011
Investigator-Initiated Study, “Role of IL-23 and other cytokines in psoriasis and atopic dermatitis pathogenesis”; PI: Andrew Blauvelt, MD

Sub-I, National Institute of Allergy and Infectious Diseases, 2008 - 2010
“ADV N Analysis of the Response of subjects with atopic Dermatitis to Oral Vitamin D₃ by Measurement of Antimicrobial Peptide Expression in Skin and Saliva (Protocol ADVN CATH 03)”; PI: Jon Hanifin, MD

Principal Investigator, Dermatology Foundation, Patient-Directed Investigation Grant, 2008 - 2009
“Effects of TNF antagonist therapy on immunity to infectious pathogens in individuals with psoriasis”

SPONSORED STUDIES

Principal Investigator, Janssen Pharmaceuticals, Inc. 2018 - PRESENT
“A phase 2, multicenter, randomized, placebo-controlled, double-blind, proof-of-concept study to evaluate guselkumab for the treatment of subjects with moderate to severe hidradenitis suppurativa”

Sub-I, AbbVie Inc. 2018 - PRESENT
“A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy”; PI: Andrew Blauvelt, MD

Sub-I, Aclaris Therapeutics, Inc. 2018 - PRESENT
“A phase 2A safety study of ATI-502 topical solution in subjects with moderate to severe atopic dermatitis.”

Sub-I, Dermira, Inc. 2018 - PRESENT
“A randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate the efficacy and safety of lebrikizumab in the patients with moderate to severe atopic dermatitis”; PI: Andrew Blauvelt

Sub-I, Dermavant Sciences Ltd. 2018 - PRESENT

“Phase 2 study to evaluate the efficacy, safety, and tolerability of RVT-501 topical ointment in pediatric patients with mild to moderate atopic dermatitis”;
PI: Andrew Blauvelt, MD

Sub-I, Eli Lilly and Company 2018 - PRESENT

“A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis (OASIS-1)”; PI: Andrew Blauvelt, MD

Sub-I, LEO Pharma A/S 2018 - PRESENT

“An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clinical trials”; PI: Andrew Blauvelt

Principal Investigator, UCB Biopharma 2018 - PRESENT

“A phase 3, multicenter, randomized, double-blind, parallel-group, placebo- and active-controlled study followed by a placebo-controlled maintenance period and open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis (CIMPACT)”;
Sub-I: 2016-2018

Sub-I, UCB Biopharma 2018 - PRESENT

“A phase 3, multicenter, double-blind, placebo-controlled study with an initial treatment period followed by a randomized withdrawal period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”;
PI: Andrew Blauvelt, MD

Sub-I, UCB Biopharma 2018 - PRESENT

“A phase 3, multicenter, randomized, double-blind study with an active-controlled initial treatment period followed by a dose-blind maintenance treatment period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD

Sub-I, UCB Biopharma 2018 - PRESENT

“A multicenter, randomized, double-blind, secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD

Sub-I, UCB Biopharma 2018 - PRESENT

“A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”;
PI: Andrew Blauvelt, MD

Sub-I, Pfizer, Inc. 2018 - PRESENT

“A phase 3 randomized, double-blind, multi-center, long-term extension study investigating the efficacy and safety of PF-04965842, with or without topical medications, administered to subjects aged 12 years and older with moderate to

severe atopic dermatitis”; PI: Andrew Blauvelt

Sub-I, Allergan plc 2018 - PRESENT
“A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis”; PI: Andrew Blauvelt, MD

Sub-I, Realm Therapeutics, Inc. 2018 - PRESENT
“A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group, Phase 2a Study to Assess the Safety and Efficacy of PRO22 Gel in Adults with Mild-to-Moderate Atopic Dermatitis”; PI: Andrew Blauvelt, MD

Principal Investigator, Vidac Pharma 2018 - PRESENT
“A Phase 2B Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects with Actinic Keratosis”

Sub-I, Athenex, Inc. 2017 - PRESENT
“A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp”; PI: Andrew Blauvelt, MD

Sub-I, LEO Pharma A/S 2017 - PRESENT
“Tralokinumab monotherapy for moderate-to-severe atopic dermatitis (ECZTRA 1)”; PI: Andrew Blauvelt, MD

Sub-I, Sienna Biopharmaceuticals, Inc. 2017 - PRESENT
“A Randomized, Double-Blind, Placebo-Controlled Phase 2b, Multicenter Study To Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib Ointment) in Subjects with Pruritus Associated with Psoriasis Vulgaris”; PI: Andrew Blauvelt, MD

Sub-I, Revance Therapeutics, Inc. 2017 - PRESENT
“An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines; PI: Robert Matheson, MD

Sub-I, Regeneron Pharmaceuticals, Inc. 2017 - PRESENT
“A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Dupilumab Monotherapy In Patients >12 To <18 Years Of Age, With Moderate-To-Severe Atopic Dermatitis”; PI: Andrew Blauvelt, MD

Sub-I, Regeneron Pharmaceuticals, Inc. 2017 - PRESENT
“An open-label, randomized, actual use study of dupilumab auto-injector device in patients with atopic dermatitis”; PI: Andrew Blauvelt, MD

Sub-I, Janssen Pharmaceuticals, Inc. 2017 - PRESENT
“A phase 3, multicenter, randomized, double-blind study evaluating the comparative efficacy of CNTO 1959 (guselkumab) and secukinumab for the treatment of moderate to severe plaque-type psoriasis (ECLIPSE)”; PI: Andrew Blauvelt, MD

<p><i>Sub-I</i>, Dermavant Sciences Ltd. “Phase 2 study of RVT-501 in adult and adolescent subjects with atopic dermatitis”; PI: Andrew Blauvelt, MD</p>	<p>2017 - PRESENT</p>
<p><i>Sub-I</i>, Allergan plc “Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipirant Tablets in Androgenetic Alopecia in Males with a Comparator Arm”; PI: Andrew Blauvelt, MD</p>	<p>2017 - PRESENT</p>
<p><i>Sub-I</i>, GlaxoSmithKline plc “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis”; PI: Andrew Blauvelt, MD</p>	<p>2017 - PRESENT</p>
<p><i>Sub-I</i>, Novartis Pharmaceuticals Corp. “A randomized, double-blind, placebo-controlled, parallel group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis (ADIPSO)”; PI: Andrew Blauvelt, MD</p>	<p>2017 - PRESENT</p>
<p><i>Sub-I</i>, AbbVie Inc. “A multicenter, open label study to assess the safety of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS)”; PI: Andrew Blauvelt, MD</p>	<p>2017 - PRESENT</p>
<p><i>Sub-I</i>, Regeneron Pharmaceuticals, Inc. “An open-label study of dupilumab in patients with atopic dermatitis who participated in previous duplimumab trials”; PI: Andrew Blauvelt, MD</p>	<p>2016 - PRESENT</p>
<p><i>Sub-I</i>, Eli Lilly and Company “A multicenter, randomized, double-blind study comparing the efficacy and safety of ixekizumab versus placebo in patients with moderate-to-severe genital psoriasis”; PI: Andrew Blauvelt, MD</p>	<p>2016 - PRESENT</p>
<p><i>Sub-I</i>, Eli Lilly and Company “A multicenter study with a randomized, double-blind placebo-controlled induction dosing period followed by a randomized maintenance dosing period and a long-term extension period to evaluate the efficacy and safety of LY2439821 in patients with moderate-to-severe plaque psoriasis (UNCOVER-1)”; PI: Andrew Blauvelt, MD</p>	<p>2016 - PRESENT</p>
<p><i>Sub-I</i>, Eli Lilly and Company “Phase III, 12-week multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of LY2438921 to etanercept and placebo in patients with moderate to severe plaque psoriasis with a long-term extension period (UNCOVER-3)”; PI: Andrew Blauvelt, MD</p>	<p>2016 - PRESENT</p>

<p><i>Sub-I</i>, Nielsen Biosciences Inc. “A phase IIa, randomized, double-blind, placebo-controlled study of the safety and efficacy of varying regimens of CANDIN for treatment of common warts (<i>verruca vulgaris</i>); PI: Andrew Blauvelt, MD</p>	2016 - PRESENT
<p><i>Sub-I</i>, Boehringer Ingelheim Pharmaceuticals, Inc. “BI 655066 versus placebo in a multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment (IMMhance); PI: Andrew Blauvelt, MD</p>	2016 - PRESENT
<p><i>Sub-I</i>, Boehringer Ingelheim Pharmaceuticals, Inc. “BI 655066 (risankizumab) versus ustekinumab and placebo comparators in a randomized double blind trial for maintenance use in moderate to severe chronic plaque type psoriasis (UltIMMa-1); PI: Andrew Blauvelt, MD</p>	2016 - PRESENT
<p><i>Sub-I</i>, Boehringer Ingelheim Pharmaceuticals, Inc. “An open label extension trial assessing the safety and efficacy of BI 655066/ABBV-o66/risankizumab administered subcutaneously in patients with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD</p>	2016 - PRESENT
<p><i>Sub-I</i>, UCB Biopharma “A phase 3, multicenter, randomized, double-blind, parallel-group, study followed by a dose-blind period and open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis (CIMPASI-2); PI: Andrew Blauvelt, MD</p>	2016 - PRESENT
<p><i>Sub-I</i>, UCB Biopharma “A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD</p>	2016 - PRESENT
<p><i>Sub-I</i>, UCB Biopharma “A multicenter, 48-week, double-blind, placebo-controlled, parallel-group extension study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD</p>	2016 - PRESENT
<p><i>Sub-I</i>, Novartis Pharmaceuticals Corp. “A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumab injections with 2 ml pre-filled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis (ALLURE)”; PI: Andrew Blauvelt, MD</p>	2016 - PRESENT
<p><i>Sub-I</i>, Novartis Pharmaceuticals Corp. “A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to</p>	2016 - PRESENT

ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY”); PI: Andrew Blauvelt, MD

Sub-I, Novartis Pharmaceuticals Corp. 2016 - PRESENT

“A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis”; PI: Andrew Blauvelt, MD

Sub-I, Merck & Co., Inc. 2016 - PRESENT

“A 52-week, phase 3, randomized, active comparator and placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (SCH 900222/MK-3222), followed by an optional long-term safety extension study, in subjects with moderate-to-severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD

Sub-I, Janssen Pharmaceuticals, Inc. 2016 - PRESENT

“Phase 3, multicenter, randomized, double-blind placebo and active comparator-controlled study evaluating the efficacy and safety of CNTO 1959 (guselkumab) in subjects with moderate to severe plaque-type psoriasis (VOYAGE-1”); PI: Andrew Blauvelt, MD

Principal Investigator, Amgen, Inc. 2014 - 2015

“A prospective, observational study to estimate the proportion of subjects with plaque psoriasis who achieve complete clearance on biologics”

Principal Investigator, National Heart, Lung and Blood Institute, 2014 - 2015

The University of Pennsylvania, and AbbVie Inc.
“A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease, The Vascular Inflammation in Psoriasis Trial and Extension”

Principal Investigator, Stiefel Laboratories, Inc. 2014 - 2015

“A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis”; Sub-I: 2013-2014

Sub-I, Novartis Pharmaceuticals Corp. 2014 - 2015

“Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFV600E Mutated Tumors”; PI: Matthew Taylor, MD

Sub-I, Anacor Pharmaceuticals, Inc. 2014 - 2015

“A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis”; PI: Eric Simpson, MD

<p><i>Sub-I</i>, Celgene Corporation “A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Atopic Dermatitis”; PI: Eric Simpson, MD</p>	2014 - 2015
<p><i>Sub-I</i>, Merck & Co., Inc. “A randomized, placebo-controlled multiple-rising dose study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of intravenous MK-8226 in adults with atopic dermatitis”; PI: Jon Hanifin, MD</p>	2013 - 2015
<p><i>Sub-I</i>, Novartis Pharmaceuticals Corp. “A Phase Ib/II, Multicenter Study of LEE011 in Combination with LGX818 in Adult Patients with BRAF Mutant Melanoma”; PI: Matthew Taylor, MD</p>	2013 - 2015
<p><i>Sub-I</i>, Regeneron Pharmaceuticals, Inc. “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of REGN668 Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis”; PI: Eric Simpson, MD</p>	2013 - 2015
<p><i>Sub-I</i>, LEO Pharma, Inc. “Safety and efficacy of escalating doses of ingenol mebutate once daily for two or three consecutive days when used on full face, full balding scalp or approximately 250 cm² on the chest in subjects with actinic keratosis. Part 2: A Phase 2, multicentre, randomised, double-blind, parallel group, vehicle-controlled, 8-week trial”; PI: Neil Swanson, MD</p>	2013 - 2015
<p><i>Sub-I</i>, Hoffman-La Roche, Ltd. “A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery”; PI: Neil Swanson, MD</p>	2013 - 2015
<p><i>Sub-I</i>, Regeneron Pharmaceuticals, Inc. “An open-label study of dupilumab in patients with atopic dermatitis who participated in previous dupilumab clinical trials”; PI: Eric Simpson, MD</p>	2013 - 2015
<p><i>Co-Principal Investigator</i>, Innovision Therapeutics “A safety and proof of concept study of topical piperine in subjects with vitiligo”; Co-PI: Amala Soumyanath, PhD</p>	2012 - 2015
<p><i>Principal Investigator</i>, Merck & Co., Inc. “A 64-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis”</p>	2012 - 2015
<p><i>Principal Investigator</i>, Amgen, Inc. “A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and</p>	2012 - 2015

Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2”

Principal Investigator, Pfizer, Inc. 2011 - 2015

“A Phase 3, Multi-Site, Open-Label Study of the Long Term Safety and Tolerability of 2 Oral Doses of CP-690,550 in Subjects With Moderate to Severe Chronic Plaque Psoriasis”

Principal Investigator, Abbott Laboratories 2011 - 2015

“A 10-Year, Post-marketing, Observational, Registry of Humira (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)”; Sub-I: 2009 - 2011

Sub-I, Amgen, Inc. 2011 - 2015

“A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects with Moderate to Severe Psoriasis”; PI: Eric Simpson, MD

Sub-I, Celgene Corporation 2011 - 2015

“A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis”; PI: Eric Simpson, MD

Principal Investigator, Pfizer, Inc. 2011 - 2014

“A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of 2 Oral Doses of CP-690,550 in Subjects With Moderate to Severe Chronic Plaque Psoriasis”

Sub-I, LEO Pharma, Inc. 2012 - 2013

“A Sequential Treatment Regimen of Cryotherapy and Picato[®] (Ingenol Mebutate) gel, 0.015% Field Therapy Compared to Cryotherapy Alone for the Treatment of Actinic Keratosis on the Face and Scalp”; PI: Neil Swanson, MD

Principal Investigator, Abbott Laboratories 2011 - 2012

“M10-016: A Phase 3, Multicenter, Open-label Continuation Study of Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study with ABT-874”; Sub-I: 2008 - 2011

Sub-I, Regeneron Pharmaceuticals, Inc. 2010 - 2012

“A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients with Moderate-to-Severe Extrinsic Atopic Dermatitis”; PI: Eric Simpson, MD

Principal Investigator, Centocor Research and Development, Inc. 2011

“A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis”; Sub-I: 2007 - 2011

<p><i>Principal Investigator</i>, Macrogenics, Inc. “A phase 2a, open label, multiple-dose study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of teplizumab in adults with moderate or more severe psoriasis”</p>	2009 - 2011
<p><i>Principal Investigator</i>, Medicis Pharmaceuticals Investigator-Initiated Study, “Tolerability comparison of clindamycin/tretinoin gel and adapelene/benzoyl peroxide gel for topical treatment of acne vulgaris”</p>	2009 - 2011
<p><i>Sub-I</i>, Amgen, Inc. “A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects with Moderate to Severe Atopic Dermatitis”; PI: Eric Simpson, MD</p>	2009 - 2011
<p><i>Sub-I</i>, Inhibitex, Inc. “FV-100 vs. Valacyclovir in Patients with Herpes Zoster”; PI: Jon Hanifin, MD</p>	2009 - 2011
<p><i>Sub-I</i>, Celgene Corporation “Celgene Apremilast for Atopic Dermatitis - A Pilot Study in Adults”; PI: Eric Simpson, MD</p>	2009 - 2011
<p><i>Sub-I</i>, Novo Nordisk, Inc. “A randomised, double-blind, placebo-controlled, single and multiple dose, dose-escalation trial of Anti-IL-20 (109-0012) 100 mg/vial in psoriatic subjects, followed by an expansion phase”; PI: Andrew Blauvelt, MD</p>	2008 - 2011
<p><i>Sub-I</i>, Basilea Pharmaceutica, Ltd. “Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy”; PI: Jon Hanifin, MD</p>	2008 - 2011
<p><i>Sub-I</i>, Taisho Pharmaceuticals R&D, Inc. “A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy, Safety and Tolerability of TS-022 in Adults with a Diagnosis of Atopic Dermatitis (AD) with Moderate to Very Severe Pruritus”; PI: Jon Hanifin, MD</p>	2009 - 2010
<p><i>Sub-I</i>, Centocor Ortho Biotech, Inc. “A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subject with Active Psoriatic Arthritis and Previously Treated with Biologic Anti-TNFα Agent(s)”; PI: Atulya Deodhar, MD</p>	2009 - 2010
<p><i>Sub-I</i>, Eli Lilly and Company “Protocol 11F-MC-RHAG(d) LY2439821 (Anti-IL-17 Humanized Antibody) Multiple-Dose Safety and Tolerability Study in Subjects with Psoriasis Vulgaris”; PI: Andrew Blauvelt, MD</p>	2008 - 2010
<p><i>Sub-I</i>, Pfizer, Inc</p>	2008 - 2009

“Phase 2A Randomized, Double-Blind, Vehicle-Controlled, Intra-Individual Comparison Trial Assessing Safety, Toleration, Pharmacokinetics, and Pilot Efficacy of 4 Weeks Treatment With Topical CP-690,550 in Chronic Plaque Psoriasis”;
PI: Andrew Blauvelt, MD

2007 - 2009

Sub-I, Gilead Science, Inc.

“A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability, and Activity of GS-9191 Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection”; PI: Eric Simpson, MD

UNFUNDED STUDIES

Sub-I, Investigator-Initiated Study,

“Secukinumab use in psoriasis patients with hepatitis C and hepatitis B”;
PI: Kevin Winthrop, MD

2017 - PRESENT

Principal Investigator, Investigator-Initiated Study,

“Ustekinumab use in psoriasis patients with hepatitis C and hepatitis B”

2014 - PRESENT

Principal Investigator, Investigator-Initiated Study,

“Pre-hydration therapy for severe psoriasis”

2014 - PRESENT

Principal Investigator, Investigator-Initiated Study,

“Repository Database of Patients Prescribed Ustekinumab Therapy at Oregon Health & Science University”

2012 - 2016

Principal Investigator, Investigator-Initiated Study,

“Clinical Database for Patients with Psoriasis”; Sub-I: 2008 – 2011

2011 - 2015

Sub-I, Investigator-Initiated Study,

“Sensitivity/specificity study of non-invasive imaging for melanoma diagnosis”;
PI: Eric Simpson, MD

2011 - 2015

Principal Investigator, Investigator-Initiated Study,

“Monitoring of patients with granuloma annulare taking combination antibiotic therapy after biopsy for mycobacterial culture”

2010 - 2011

Sub-I, Investigator-Initiated Study,

“Presence of Gadolinium in the Tissue of Patients with Nephrogenic Systemic Fibrosis”;
PI: Eric Simpson, MD

2009 - 2011

Sub-I, Investigator-Initiated Study,

“Staphylococcal colonization and the subsequent risk of serious infection in rheumatic disease patients receiving biologic therapy; a role for decolonization?”;
PI: Kevin Winthrop, MD

2006 - 2011

PEER-REVIEWED PUBLICATIONS

Cushing, M. and **B.D. Ehst**. (2017, in press). Valsalva purpura in labor. *The New England Journal of Medicine*.

Mott, S.E., Z.G. Pena, R.I. Spain, K.P. White and **B.D. Ehst**. (2016). Nicolau syndrome and localized panniculitis: a report of dual diagnoses with an emphasis on morphea profunda-like changes following injection with glatiramer acetate. *The Journal of Cutaneous Pathology* 43(11):1056-61.

Patel, A.B., A.R. Solomon, M.J. Mauro and **B.D. Ehst**. (2016). Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia. *Dermatology* 232(1):122-5.

Papp, K.A., M.A. Menter, M. Abe, B. Elewski, S.R. Feldman, A.B. Gottlieb, R. Langley, T. Luger, D. Thaci, M. Buonanno, P. Gupta, J. Proulx, S. Lan, R. Wolk; **OPT Pivotal 1 and OPT Pivotal 2 investigators**. (2015). Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. *The British Journal of Dermatology*. 143(4):949-61.

Garg, N., B. Truong, J.H. Ku, T.S. Devere, **B.D. Ehst**, A. Blauvelt and A.A. Deodhar. (2015). A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic. *Clinical Rheumatology* 34(10):1745-51.

Truong, B., N. Rich-Garg, **B.D. Ehst**, A.A. Deodhar, J.H. Ku, K. Vakil-Gilani, A. Danve and A. Blauvelt. (2015). Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. *Clinical, Cosmetic and Investigational Dermatology* 8:563-9.

Varley, C.D., A.A. Deodhar, **B.D. Ehst**, A. Bakke, A. Blauvelt, R. Vega, S. Yamashita and K.L. Winthrop. (2014). Persistence of *Staphylococcus aureus* colonization among individuals with immune-mediated inflammatory diseases treated with TNF- α inhibitor therapy. *Rheumatology* 53(2):332-7.

Simpson, B., S. Foster, J.H. Ku, E.L. Simpson and **B.D. Ehst**. (2014). Triple antibiotic combination therapy may improve but not resolve granuloma annulare. *Dermatologic Therapy* 27(6):343-7.

Ku, J.H., K.L. Winthrop, C.D. Varley, A. Sullivan, **B.D. Ehst**, A. Blauvelt and A.A. Deodhar. (2013). Implications for biologic therapy: *Staphylococcus aureus* decolonization of individuals with a history of recurrent skin and soft tissue infection. *JAMA Dermatology* 149(8):986-9.

Jack, A., M.J. Mauro and **B.D. Ehst**. (2013). Pityriasis rubra pilaris-like eruption associated with the multi-kinase inhibitor ponatinib. *The Journal of the American Academy of Dermatology* 69(5):e249-50.

Griffith-Bauer, K., M. O'Hearn and **B.D. Ehst**. (2012). Chronic ulcerative herpes simplex virus infection of the vulva. *Case Reports in Dermatology* 4:192-6.

Goreshi, R., A. Samrao and **B.D. Ehst**. (2012). Double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. *The Journal of Drugs in Dermatology* 11(12):1422-6.

Perez-Rodriguez, J., S. Lai, **B.D. Ehst**, D.M. Fine and D.A. Bluemke. (2009). Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment—report of 33 cases. *Radiology* 250(2):371-7.

Knol A.C., **B.D. Ehst**, A. Dompmartin, G. Quéreux, J.M. Nguyen, F. Comoz, J.J. Renaut, A. Khammari, E.C. Vonderheid and B. Dréno. (2009). Toll-like receptor 2, 4, 7 and 9 expression in primary cutaneous CD30+ T-cell lymphoma. *The British Journal of Dermatology* 161(6):1414-6.

Ehst, B.D., B. Dréno and E.C. Vonderheid. (2008). Primary cutaneous CD30+ anaplastic large cell lymphoma responds to imiquimod cream. *The European Journal of Dermatology* 18(4):467-8.

Fonder, M.A., D.L. Cummins, **B.D. Ehst**, G.J. Anhalt and J.H. Meyerle. (2006). Adalimumab therapy for recalcitrant pyoderma gangrenosum. *The Journal of Burns and Wounds* 5:66-71.

Janssen, E.M., N.M. Droin, E.E. Lemmens, M.J. Pinkoski, S.J. Bensinger, **B.D. Ehst**, T.S. Griffith, D.R. Green, S.P. Schoenberger. (2005). CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. *Nature* 434(7029):88-93.

Richards, D.M., S.L. Dalheimer, **B.D. Ehst**, T.L. Vanasek, M.K. Jenkins, M.I. Hertz and D.L. Mueller. (2004). Indirect minor histocompatibility antigen presentation by allograft recipient cells in the draining lymph node leads to the activation and clonal expansion of CD4⁺ T cells that cause obliterative airways disease. *The Journal of Immunology* 172(6):3469-3479.

Ehst, B.D. and E.M. Warshaw. (2004). Alcohol-induced, application site-erythema after topical immunomodulator use and its inhibition by aspirin. *The Archives of Dermatology* 140(8):1014-1015.

Ehst, B.D., E. Ingulli and M.K. Jenkins. (2003). Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. *The American Journal of Transplantation* 3(11):1355-1362.

Itano, A.A., S.J. McSorley, R.L. Reinhardt, **B.D. Ehst**, E. Ingulli, A.Y. Rudensky and M.K. Jenkins. (2003). Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. *Immunity* 19(1):47-57.

McSorley, S.J., **B.D. Ehst**, Y. Yu and A.T. Gewirtz. (2002). Bacterial flagellin is an effective adjuvant for CD4⁺ T cells in vivo. *The Journal of Immunology* 169:3914-3919.

Sperling, A.I., J.A. Auger, **B.D. Ehst**, I.C. Rulifson, C.B. Thompson and J.A. Bluestone. (1996). CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. *The Journal of Immunology* 157:3909-3917.

REVIEWS

Ehst, B.D., K. Minzer-Conzetti, A. Swerdlin and T.S. Devere. (2010). Cutaneous manifestations of internal malignancy. *Current Problems in Surgery* 47(5):377-448.

BOOK CHAPTERS

Ehst, B.D. and A. Blauvelt. (2012). Skin disease in acute and chronic immunosuppression. Chapter in *Fitzpatrick's Dermatology in General Medicine, 8th Edition*.

OTHER PUBLICATIONS

Winthrop, K.L., S.A.R. Siegel, L. Chen, H. Yun, B. Chan, J.W. Baddley, **B.D. Ehst** and J.R. Curtis. (2016). Comparative infectious risk of immunosuppressive therapies used in psoriasis. *Journal of Psoriasis and Psoriatic Arthritis* 2(1):44-50.

Curtis, J.R., M.I. Danila, L. Chen, B. Chan, **B. Ehst**, F. Xie, K.L. Winthrop and H. Yun. (2016). Risk of cardiovascular outcomes among psoriasis patients treated with biologics and other systemic agents. *Journal of Psoriasis and Psoriatic Arthritis* 1(3):128-37.

Ehst, B.D. (2013). Oral hairy leukoplakia. *CDS: Dermatology Online*; <http://www.decisionsupportinmedicine.com/>

Blauvelt, A. and **B.D. Ehst**. (2012). Pathophysiology of psoriasis. In B. Rose (Ed.), *UpToDate*. Available from <http://www.uptodate.com/home>

Ehst, B.D. and B.A. Cohen (2006). Case of the month: *Staphylococcus aureus* abscess due to “skin popping.” *Johns Hopkins Advanced Studies in Medicine* 6(3&4):151&198. Available at <http://www.jhasim.com/index.cfm>

Ehst, B.D. (2002). Design and Characterization of a Model of Murine Skin Graft Rejection: Visualizing the Immune Response Against a Defined Minor Transplantation Antigen. *Dissertation Abstracts International*, 62(11), 5019. (UMI No. 3034442)

PUBLICATIONS IN PROGRESS

Siegel, S., J.H. Ku, K. L. Winthrop, W. Naugler and **B.D. Ehst**. (2018, accepted). Ustekinumab use in patients with severe psoriasis with hepatitis B and/or C. *The British Journal of Dermatology*.

Beeram, A., E. Hill, **B.D. Ehst**, T. Hajar and E. Simpson. (2018, submitted). Effectiveness of intensive topical therapeutic regimens in hospitalized patients with psoriasis exacerbations.

Hickok, R., Z. Pena and **B.D. Ehst**. (in preparation). Kimura disease in a caucasian male: a rare cause of head and neck mass with lymphadenopathy.

Le, C., J.H. Ku, A.A. Deodhar and **B.D. Ehst**. (in preparation). Real-world use of ustekinumab for psoriasis, including palmar-plantar disease, and psoriatic arthritis: a comprehensive, retrospective chart review of an academic outpatient clinic.

CONFERENCE PRESENTATIONS/POSTERS

Siegel, S.A.R., K.L. Winthrop, **B.D. Ehst** and A.G. Ortega-Loayza. (2017, April). *Secukinumab treatment of individuals with psoriasis infected with hepatitis B and/or hepatitis C virus*. Poster presentation given at the 76th Annual Meeting of the Society of Investigative Dermatology, Portland, OR.

Winthrop, K.L., S.A.R. Siegel, L. Chen, B. Chan, J.W. Baddley, A.J. Taylor, H. Yen, **B.D. Ehst** and J.R. Curtis. (2015, June). *Risk of herpes zoster and non-viral opportunistic infection in a psoriatic cohort*. Poster presentation given at the 23rd World Congress of Dermatology, Vancouver, British Columbia.

Li, C., A.A. Deodhar and **B.D. Ehst**. (2015, June). *“Real-world” use of ustekinumab for psoriasis, including palmar-plantar disease, and psoriatic arthritis: a comprehensive, retrospective chart review of an academic outpatient clinic*. Poster presentation given at the 23rd World Congress of Dermatology, Vancouver, British Columbia.

Siegel, S., K.L. Winthrop, W. Naugler and **B.D. Ehst**. (2015, May). *Ustekinumab treatment of psoriatics infected with hepatitis B and/or hepatitis C*. Poster presentation given at the 75th Annual Meeting of the Society of Investigative Dermatology, Atlanta, GA.

Patel, A., A. Solomon, M. Mauro and **B.D. Ehst**. (2015, May). *Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia*. Poster presentation given at the 75th Annual Meeting of the Society of Investigative Dermatology, Atlanta, GA.

Golden, S., M. Heinrich and **B.D. Ehst**. (2015, January). *Ponatinib-Induced Pityriasis Rubra Pilaris-Like Eruption: A Report of Six Cases*. Poster presentation given at the 2015 Maui Dermatology Conference, Maui, HI.

Simpson, B., S. Foster, J.H. Ku, E.L. Simpson and **B.D. Ehst**. (2013, May). *Triple antibiotic combination therapy may improve but not resolve granuloma annulare*. Poster presentation given at the 2013 International Investigative Dermatology Meeting, Edinburgh, Scotland.

Liu, Y., D. McClanahan, S. Persaud, Y. Wang and **B. Ehst**. (2013, May). *The loss of Piasy activates IL-23 expression from keratinocytes in response to IL-17 and TNF α , a positive feedback mechanism for Th17 activation in psoriasis*. Poster presentation given at the 2013 International Investigative Dermatology Meeting, Edinburgh, Scotland.

Garg, A., B. Truong, J. Ku, A. Blauvelt, **B. Ehst** and A. Deodhar. (2012, November). *Simple questions in the dermatology office may reasonably exclude, but do not reliably identify psoriatic arthritis patients: results from the Center of Excellence for Psoriasis and Psoriatic Arthritis*. Poster presentation given at the 76th Annual Scientific Meeting of the American College of Rheumatology, Washington, DC.

Garg, A., B. Truong, J. Ku, A. Blauvelt, **B. Ehst** and A. Deodhar. (2012, June). *Simple questions in the dermatology office may reasonably exclude, but do not reliably identify psoriatic arthritis patients: results from the Center of Excellence for Psoriasis and Psoriatic Arthritis*. Oral and poster presentation given at the 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Stockholm, Sweden.

Goreshi, R., A. Samrao and **B.D. Ehst**. (2012, May). *Double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene*. Oral and poster presentation given at the 72nd Annual Meeting of the Society of Investigative Dermatology, Raleigh, NC.

Varley, C.D., K. Griffith-Bauer, A.A. Deodhar, **B.D. Ehst**, A. Bakke, A. Blauvelt, R. Vega and K.L. Winthrop. (2011, July). *Higher prevalence of Staphylococcus aureus colonization in psoriatic patients may predispose to*

incident infections. Oral and poster presentation given at the 2011 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Naples, Italy.

Samrao, A., B. Truong, A. Deodhar, J. Gelfand, T. Devere, **B. Ehst** and A. Blauvelt. (2011, May). *High prevalence of psoriatic arthritis with a significant impact on quality of life in psoriasis patients evaluated at a multidisciplinary center*. Poster presentation given at the 71st Annual Meeting of the Society of Investigative Dermatology, Phoenix, AZ.

Griffith-Bauer, K., C.D. Varley, K.L. Winthrop, A. Blauvelt, A.A. Deodhar, A. Bakke, R. Vega and **B.D. Ehst**. (2011, May). *Staphylococcus aureus colonization does not increase the rate of infection among psoriasis patients using biologic therapy*. Poster presentation given at the 71st Annual Meeting of the Society of Investigative Dermatology, Phoenix, AZ.

Varley, C., A.A. Deodhar, **B. Ehst**, A. Bakke, A. Blauvelt, R. Vega and K. Winthrop. (2010, November). *Colonization and Infection by Staphylococcus Aureus Among Those Using Biologic Therapy*. Oral and poster presentation given at the 74th Annual Scientific Meeting of the American College of Rheumatology, Atlanta, GA

Deodhar, A.A., S. Yamashita, **B. Ehst**, A. Bakke, A. Blauvelt, B. Andrews, R. Vega and K. Winthrop. (2009, October). *Prevalence of Staphylococcus Aureus Colonization Among Those Using Biologic Therapy*. Poster presentation given at the 73rd Annual Scientific Meeting of the American College of Rheumatology, Philadelphia, PA

Ehst, B.D. and F. Tausk. (2006, March). *Annular elastolytic granuloma: A case and discussion*. Oral presentation given at the Gross & Microscopic Dermatology Symposium at the 64th Annual American Academy of Dermatology Meeting, San Francisco, CA.

Ehst, B.D. (2001, October). *Contributions of CD4 and CD8 T cells in the rejection of skin allografts*. Oral presentation given at the University of Minnesota Medical School Annual M.D./Ph.D. Conference, Minneapolis, MN.

Ehst, B.D. and M.K. Jenkins. (2001, May). *Acute rejection of a skin graft expressing a defined minor antigen*. Oral presentation given at Transplant 2001, the Joint American Transplant Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL.

Ehst, B.D. and M.K. Jenkins. (2001, January). *Acute rejection of a skin graft expressing a defined minor antigen*. Poster presentation given at the Keystone Symposia on Regulation of Immunity and Autoimmunity, Keystone, CO.

Ehst, B.D. and M.K. Jenkins. (2000, November). *Visualization of the immune response against a skin graft expressing a single model minor antigen*. Oral and poster presentation given at the 29th Annual Autumn Immunology Conference, Chicago, IL.

Ehst, B.D., K.A. Pape and M.K. Jenkins. (2000, May). *Antigen-specific CD4⁺ cells prolong the clonal expansion of CD8⁺ cells*. Poster presentation given at Immunology 2000, the American Association of Immunologists and Clinical Immunology Society Joint Annual Meeting, Seattle, WA.

Ehst, B.D. and M.K. Jenkins. (1999, November). *Development of a murine model of skin graft rejection*

across a single minor-antigenic disparity. Oral and poster presentation given at the 28th Annual Autumn Immunology Conference, Chicago, IL.

Ehst, B.D., A.I. Sperling and J.A. Bluestone. (1996, May). *Requirements for activation and proliferation of TCR $\gamma\delta$ intestinal intraepithelial lymphocytes.* Poster presentation given at the University of Chicago Senior Biological Sciences Honors Forum, Chicago, IL.

Ehst, B.D., A.I. Sperling, J.A. Auger, I.C. Rulifson and J.A. Bluestone. (1995, November). *Costimulation but not TCR ligation regulates late T Cell expansion and survival.* Oral and poster presentation given at the 24th Annual Autumn Immunology Conference, Chicago, IL.

INVITED LECTURES

International/National

Ehst, B.D. (2018, September). *Atopic dermatitis: Past, present and future.* Lecture given at the 2018 Annual Meeting of the American Society of Allergy Nurses, Seaside, OR.

Ehst, B.D. (2018, February). *Update on HIV and the Skin.* Lecture given at the Dermatology Nurses' Association's 36th Annual Convention, San Diego, CA.

Ehst, B.D. (2017, March). *Update on HIV and the Skin.* Lecture given at the Dermatology Nurses' Association's 35th Annual Convention, Orlando, FL.

Ehst, B.D. (2015, March). *Tumor necrosis factor inhibitors: Pre-treatment workup, dosing and monitoring.* Lecture given at the 73rd Annual American Academy of Dermatology Meeting, San Francisco, CA.

Ehst, B.D. (2012, March). *Update on HIV Skin Disease.* Lecture given at the Dermatology Review Course at the 70th Annual American Academy of Dermatology Meeting, San Diego, CA.

Ehst, B.D. (2011, March). *Infectious diseases and STDs in Dermatology.* Lecture given at the Dermatology Nurses' Association's 29th Annual Convention, San Diego, CA.

Ehst, B.D. (2011, February). *Update on HIV Skin Disease.* Lecture given at the Dermatology Review Course at the 69th Annual American Academy of Dermatology Meeting, New Orleans, LA.

Regional/Local

Ehst, B.D. (2016, October). *What's new in psoriasis?* Lecture given at the Dermatology Update Conference, Continuing Education for Primary Care series, HealthPartners Institute, St. Louis Park, MN.

Ehst, B.D. (2015, January). *Update on HIV and the Skin; Psoriasis Potpourri.* Lectures given at the biennial meeting of the Idaho Dermatology Society, Boise, ID.

Ehst, B.D. (2014, February). *HIV and Dermatology Update.* Lecture given at the monthly meeting of the Oregon Dermatology Society, Portland, OR.

Ehst, B.D. (2013, October). *Psoriasis Update: Current and future therapies*. Lecture given at the 1st Annual Oregon Society of Dermatology Associates meeting, Portland, OR.

Ehst, B.D. (2013, September). *Psoriasis Update: Co-morbidities*. Lecture given at the 9th Annual Dermatology for Primary Care Update meeting, Portland, OR.

Ehst, B.D. (2013, May). *Dermatologic unknowns*. Talk given to the Oregon Dermatologic Physician Assistant's Society, Portland, OR.

Ehst, B.D. (2013, February). *Treatment of common skin conditions*. Lecture given at the 23rd Annual Lane County Nurse Practitioner Conference, Eugene, OR.

Ehst, B.D. (2012, November). *Skin manifestations and mimics of infectious disease, parts 1 and 2*. Lectures given at the 22nd Annual Meeting of the Infectious Diseases Society of Oregon, Eugene, OR.

Ehst, B.D. (2012, March). *Dermatologic unknowns*. Lecture given at the 22nd Annual Lane County Nurse Practitioner Conference, Eugene, OR.

Ehst, B.D. (2011, September). *Dermatologic unknowns*. Lecture given at the 7th Annual Dermatology for Primary Care Update meeting, Portland, OR.

Ehst, B.D. (2011, April). *Old and New Issues in HIV Skin Disease*. Lecture given at the April breakfast meeting of the Northwest AIDS Education and Training Center, Portland, OR.

Ehst, B.D. (2010, February). *Common skin conditions*. Lecture given at the Breakout Session of the 41st Annual Primary Care Review conference, Portland, OR.

Ehst, B.D. (2009, September). *Body-modification: tattoos and piercings*. Lecture given at the 5th Annual Dermatology for Primary Care Update meeting, Portland, OR.

Ehst, B.D. (2009, August). *MRSA update*. Lecture given at the 61st Annual Pacific Dermatologic Association meeting, Portland, OR.

Ehst, B.D. (2009, February). *Body-modification: tattoos and piercings*. Lecture given at the Pediatrics Plenary Session of the 40th Annual Family Medicine & Primary Care Review conference, Portland, OR.

Ehst, B.D. (2009, January). *Current issues in HIV skin disease*. Talk given to the Oregon Dermatologic Physician Assistant's Society, Beaverton, OR.

Ehst, B.D. (2006, November). *Nephrogenic systemic fibrosis*. Lecture given at Grand Rounds, Department of Nephrology, Johns Hopkins Bayview Medical Center, Baltimore, MD.

Ehst, B.D. (2002, September). *Visualizing T cells in skin allografts*. "Dermatologic Research in Progress" lecture given at Grand Rounds, Department of Dermatology, Indiana University, Indianapolis, IN.

SPEAKING ENGAGEMENTS

COSENTYX® (secukinumab): A Comprehensive Approach to Treating Moderate to Severe Plaque Psoriasis.

National speaker board webinars, lunch and dinner talks on behalf of Novartis Pharmaceuticals, Inc.; Lake Oswego, OR 8/24/17, 3/5/18; Palo Alto, CA 8/30/17; Portland, OR 9/6/17, 9/15/17, 9/19/17, 4/19/18, 6/4/18, 7/16/18, 8/21/18, 9/24/18; Fresno, CA 11/16/17; Roseburg, OR 11/30/17; Medford, OR 12/6/17; Eugene, OR 2/20/18; Bend, OR 2/22/18; Salem, OR 3/2/18

DUPIXENT® (dupilumab): The First Biologic for Adults With Uncontrolled Moderate-to-Severe Atopic Dermatitis. National speaker board product theaters, webinars, lunch and dinner talks on behalf of Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis US, LLC; Spokane, WA 12/7/17; Roseburg, OR 12/18/17; Hillsboro, OR 1/26/18; Portland, OR 2/7/18, 4/11/18, 4/30/18, 5/10/18, 6/5/18, 8/14/18; Lake Oswego, OR 3/16/18; Salem, OR 4/19/18; San Francisco, CA 7/27/18; Bend, OR 8/16/18; Sunriver, OR 8/18/18; Girdwood, AK 9/8/18; Seaside, OR 9/28/18

TALTZ® (ixekizumab): A Closer Look at Taltz. National speaker board breakfast, lunch and dinner talks on behalf of Lilly USA, LLC; Bend, OR 2/23/18; Honolulu and Kailua, HI 3/28/18, 3/29/18, 3/30/18; Hillsboro, OR 4/6/18; Pasco, WA 4/26/18; Portland, OR 5/23/18, 7/19/18; Astoria, OR 6/14/18; Salem, OR 7/26/18; Kihei, Wailuku and Paia, HI 8/30/18, 8/31/18; Olympia, WA 10/4/18

OTHER PROFESSIONAL PRESENTATIONS

Psoriasis comorbidities. Lecture given for the Early Careers symposium of “Psoriasis Day” event (September, 2018) on behalf of the National Psoriasis Foundation and Oregon Health & Science University, Portland, OR.

Updates in Psoriasis. Lecture given for the Central Oregon Advanced Practice Providers Network (2018, February) on behalf of the National Psoriasis Foundation, Bend, OR.

Psoriasis 101. Lecture given at internal medicine grand rounds (2017, November) on behalf of the National Psoriasis Foundation, Legacy Emmanuel Hospital, Portland, OR.

Targets, Treatments, and What it Means for You. Lecture given at the ‘More Than Skin Deep’ event (2017, April) of the National Psoriasis Foundation, Portland, OR.

Pathogenesis and Genetics of Psoriasis and PsA; Management of Psoriasis and PsA- Biologics. Lectures given at the NPF-GRAPPA collaborative series ‘Advancing Knowledge and Practice in Psoriasis and Psoriatic Arthritis’ meeting (2015, May), Portland, OR.

Psoriatic Arthritis. Lecture given at the ‘Be Joint Smart’ conference (2012, October) of the National Psoriasis Foundation and the Arthritis Foundation, Portland, OR

Desai, N. and **B.D. Ehst.** (2011, February). *A “Bee”wildering rash.* Presented at the Gross & Microscopic Dermatology Symposium at the 69th Annual American Academy of Dermatology Meeting, New Orleans, LA.

N. Desai and **B.D. Ehst.** (2009, August). *Borderline lepromatous leprosy.*

K. White, **B.D. Ehst** and C. White. (2009, August). *Eruptive disseminated spitz nevi.*

K. Minzer-Conzetti and **B.D Ehst.** (2009, August). *Huriez syndrome.*

Case presentations at the 61st Annual Pacific Dermatologic Association meeting, Portland, OR.

Ehst, B.D. (2004 - 2007, Spring & Fall). *Case presentations.* Semiannual Maryland Dermatologic Society Meeting, The Johns Hopkins Hospital, Baltimore, MD.

SERVICE

PROFESSIONAL AFFILIATIONS

American Academy of Dermatology
American Association of Immunologists
American Medical Association
Combined Psoriasis and Psoriatic Arthritis Clinics and Centers of North America
Dermatology Foundation
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
National Psoriasis Foundation
Oregon Dermatology Society
Oregon Medical Association
Society for Investigative Dermatology

EDITORIAL ACTIVITIES

<i>Ad hoc reviewer, BioDrugs</i>	2018 - PRESENT
<i>Ad hoc reviewer, Clinical and Experimental Dermatology</i>	2014 - PRESENT
<i>Ad hoc reviewer, Dermatology Research and Practice</i>	2014 - PRESENT
<i>Ad hoc reviewer, Association of American Medical Colleges, Monographs</i>	2007 - PRESENT
<i>Faculty Member, Section of Psoriasis & Other Inflammatory Diseases,</i> <i>Faculty of 1000, http://www.fiooo.com/</i>	2013 - 2016
<i>Ad hoc reviewer, National Institute of Standards and Technology,</i> <i>U.S. Department of Commerce</i>	2013
<i>Ad hoc reviewer, International Journal of STD & AIDS</i>	2013

COMMITTEES

<i>Member, Clinician Improvement and Satisfaction Committee</i> <i>Dermatology group, HealthPartners, St. Paul, MN</i>	2015 - 2017
<i>Member, Departmental Budget Committee</i> <i>Department of Dermatology, Oregon Health & Science University, Portland, OR</i>	2014 - 2015
<i>Chair, Departmental Operations Improvement Committee</i> <i>Department of Dermatology, Oregon Health & Science University, Portland, OR</i>	2014 - 2015
<i>Member, Clinical Competency Committee</i> <i>Department of Dermatology, Oregon Health & Science University, Portland, OR</i>	2013 - 2015
<i>Member, Faculty Executive Committee</i> <i>Department of Dermatology, Oregon Health & Science University, Portland, OR</i>	2010 - 2013

<i>Member, Clinical Faculty Guideline Committee</i> Department of Dermatology, Oregon Health & Science University, Portland, OR	2008 - 2013
<i>Representative, House Staff Council</i> The Johns Hopkins Hospital, Baltimore, MD	2004 - 2007
<i>Resident Representative, Transitional Residency Coordinating Committee</i> Hennepin County Medical Center, Minneapolis, MN	2003 - 2004
<i>Resident Representative, Graduate Medical Education Committee</i> Hennepin County Medical Center, Minneapolis, MN	2003 - 2004
<i>Representative, Resident Council</i> Hennepin County Medical Center, Minneapolis, MN	2003 - 2004
VOLUNTEER ACTIVITIES	
<i>Local Moderator, NPF-GRAPPA collaborative series 'Advancing Knowledge and Practice in Psoriasis and Psoriatic Arthritis' meeting, Portland, OR</i>	MAY 2015
<i>Faculty Leader, Dermatology Student Interest Group</i> Oregon Health & Science University, Portland, OR	2013 - 2015
<i>Member, Executive Committee</i> Oregon Dermatology Society, Portland, OR	2012 - 2015
<i>Volunteer, Botswana-UPenn Partnership</i> Princess Marina Hospital, Gaborone, Botswana	JAN 2014
<i>Co-director, Dermatology Review Course at the 70th Annual American Academy of Dermatology Meeting, San Diego, CA</i>	MAR 2012
<i>Secretary/Treasurer,</i> Oregon Dermatology Society, Portland, OR	2011 - 2012
<i>Fundraiser, Vice-chair for the State of Oregon</i> Dermatology Foundation, Evanston, IL	2009 - 2011
<i>Coordinator for Departmental Grand Rounds, Department of Dermatology</i> Johns Hopkins University School of Medicine, Baltimore, MD	2006 - 2007
<i>Coordinator for Visiting Physicians, Department of Dermatology</i> Johns Hopkins University School of Medicine, Baltimore, MD	2005 - 2006
<i>Volunteer, Smiley's Family Practice Clinic</i> Fairview-University Medical Center, Minneapolis, MN	1998 - 2003

SPECIALIZED CLINICAL ACTIVITIES

OHSU Dermatologic Clinic for HIV/AIDS 2009 - 2015
Established first subspecialty clinic at OHSU focusing on cutaneous issues in individuals with HIV/AIDS

OHSU Center for Excellence in Psoriasis and Psoriatic Arthritis 2008 - 2015
Member (2008 - 2015) and *Co-Director* (2011 - 2015) of clinical team focusing on comprehensive multidisciplinary care for patients living with psoriasis and psoriatic arthritis

CONTINUING EDUCATION

Participant, Pathways to Leadership Course 2011
Oregon Health & Science University, Portland, OR

TEACHING

Educator's Portfolio available upon request

HONORS AND AWARDS

Recipient, Department of Dermatology Faculty Teaching Award, 2015
Oregon Health & Science University

Portland Monthly magazine's "Top Doctors" 2012, 2015

Participant, National Institutes of Health Medical Scientist Training Program 1996 - 2003

Recipient, J. Thomas Livermore Award in Hematology, APR 2002
Minnesota Medical Foundation

Recipient, Young Investigator Award, Joint American Transplant Meeting of the MAY 2001
American Society of Transplant Surgeons and American Society of Transplantation

Recipient, National Institutes of Health Pre-Doctoral Training Grant in Immunology 1999 - 2001

Medical School Honors, University of Minnesota Medical School 1996 - 1997

Dean's List, University of Chicago 1992 - 1996

Recipient, Howard Hughes Summer Research Fellowship JUN 1995